Autoimmune hemolytic anemia (AIHA) and cryoglobulinemia, occur at diagnosis or later both in 10-20% of patients with Waldenströ m's Macroglobulinemia (WM). 1, 2 Immunoglobulin G fragment C (Fcg)-mediated erythrophagocytosis has been recognized as the major pathogenic mechanism responsible for AIHA. 3, 4 The clearance of immune complexes and the efficacy of their phagocytosis by splenic macrophages depend on the interactions between Fcg receptors (FcgR) and immunoglobulin G (IgG). 3 Therefore, genetic polymorphisms that modulate the affinity of FcgRIIa and FcgRIIIa for IgG may influence these processes. The phenotypic expression of valine (V) or phenylalanine (F) at amino acid 158 of FcgRIIIa receptor (FcgRIIIa-158V/ F polymorphism) is associated with higher or lower affinity for IgG1 and IgG3. 3 Consequently, the homozygous FcgRIIIa-158F genotype is associated with a lower response rate to rituximab therapy. 2 Similarly, FcgRIIa gene displays a G to A point mutation in the ligand binding domain, causing an arginine (R) to histidine (H) amino-acid substitution at position 131. 3 Both alleles bind IgG1 and IgG3. The FcgRIIa-131H allele has a higher affinity for IgG2 than FcgRIIa-131R allele, 3 whereas FcgRIIa-131R is more efficient than FcgRIIa-131H for mediating C-reactive protein (CRP)-dependent phagocytosis.
5 C-reactive protein is an acute phase serum protein involved in the recognition of products of damaged autologous cells, and elevated serum concentrations have been described in lymphoproliferative disorders, especially WM. In addition, the FcgRIIa is involved in immune complex and cryoglobulin-induced production of cytokines, such as interleukin (IL)-6 and IL-10, two cytokines of importance for B-cell malignant disorders. 6 The FcgRIIa-R/H131 polymorphism influences the development of several autoimmune disorders such as systemic lupus erythematosus. 3 Therefore, we evaluated the relationships between the FcgRIIa-131R/H and FcgRIIIa-158V/F polymorphisms, and clinical characteristics including AIHA and cryoglobulinemia in 74 WM patients.
Seventy-four patients, with WM diagnosed and treated according to the recommendations established during the second International Workshop on WM, 2 were included in the study. Median age was 64 years (range 39-98 years, M/F ¼ 2) and informed consent was obtained from all patients according to local institutions guidelines. Autoimmune hemolytic anemia was defined by the combination of an anemia (hemoglobin o12 g/ dl), one or more laboratory signs of hemolysis (reticulocytosis, decreased haptoglobin, increased bilirubin, or lactic dehydrogenase) and the presence of antierythrocyte autoantibody detected by the direct antiglobulin test (DAT). Treatment initiation criteria 2 and all AIHA diagnostic criteria, including positive DAT were assessed every 6 months. Twenty-two patients (29%) with asymptomatic WM remained untreated at the date of the analysis. First-line therapy included chlorambucil (39 patients), combination chemotherapy (2), fludarabine alone (6) or in combination with other chemotherapy (3), and rituximab alone (2) . Rituximab and fludarabine were delivered later in 10 and 14 additional patients, respectively. There was no difference in the number of treatments, the use of fludarabine and rituximab between the genotypic groups. Genomic DNA was extracted from peripheral blood using standard phenol-chloroform method. Genotyping for FcgRIIa-131R/H and FcgRIIIa-158V/F polymorphisms were performed with a PCR-based restriction fragment length polymorphism assay. The clinical and laboratory characteristics in the different genotypic groups were compared using the Yates modified w 2 -test or the Fisher exact test. Cumulative incidences of competing risks were computed as previously described, estimates in each group of patients were compared with the test proposed by Gray. Survival after first treatment initiation and overall survival were calculated from the date of the first-line therapy initiation and the date of diagnosis, respectively, to the date of death or last follow-up evaluation, in the 59 patients diagnosed before 1 December 2003. The stopping date was 31 January 2005 and median follow-up of alive patients was 55 months (14-253). Survival curves were compared using the log-rank test with bootstrap resampling (1000 replicates). All analyses were carried out using Splus 6.2 (MathSoft, Cambridge, MA, USA) software and the R1.8.1 language, especially the cmprsk package (2.1-3 version) developed by Gray (Cambridge, MA, USA).
Twenty-three patients (31%) were FcgRIIa-131RR homozygous, 19 (26%) FcgRIIa-131HH homozygous, and 32 (43%) were heterozygous (FcgRIIa-131RH). Sixteen patients (21%) were FcgRIIIa-148FF homozygous. The gene frequencies of FcgRIIa-131 H and FcgRIIIa-158F were 0.42 and 0.45, respectively, as expected in a general Caucasian population. FcgRIIa-131HH patients more frequently presented with anemia (P ¼ 0.02), thrombocytopenia (P ¼ 0.0004) and multiple cytopenias at diagnosis (P ¼ 0.001), whereas anemia (P ¼ 0.04), and thrombocytopenia (P ¼ 0.01) were less frequent in FcgRIIa-131RR patients (Table 1) . Direct antiglobulin test detected IgG in 11 patients (15%) and C3d alone in two patients with symptomatic cold agglutinin disease. IgG-mediated AIHA was recorded in six other patients. Thus, AIHA occurred in eight patients, 0-228 months after diagnosis (median: 39 months). No AIHA occurred during fludarabine therapy. Cryoglobulinemia was found in 13 patients (17.6%) at diagnosis (type I: 8, type II: 1, and undetermined: 4). No patient had autoimmune thrombocytopenia. FcgRIIa-131HH patients more frequently had cryoglobulinemia (P ¼ 0.03), IgG-positive DAT (P ¼ 0.02), AIHA (P ¼ 0.02) and a higher cause specific cumulative incidence of AIHA (P ¼ 0.02). Significant differences in frequency and cumulative incidence of IgG-mediated AIHA were also found between FcgRIIa-131HH patients and remaining patients. There was no significant difference in the frequencies of warm AIHA neither between the two homozygous groups (P ¼ 0.38), nor between FcgRIIa-131RR patients and FcgRIIa-131RH patients (P ¼ 0.18). FcgRIIa-131R/H polymorphism was also a prognostic factor for survival after first treatment initiation (P ¼ 0.05, Figure 1 ). FcgRIIa-131HH and FcgRIIa-131RR patients had a similar survival after first treatment initiation (P ¼ 0.80), but shorter survival estimates than FcgRIIa-131RH patients (P ¼ 0.012 and 0.05, respectively). In addition, FcgRIIa-131HH patients had a shorter overall survival than FcgRIIa-131RH patients (P ¼ 0.024). By contrast, there was no significant difference in overall survival or clinical presentation according to FcgRIIIa-158V/F polymorphism status. The prognostic value of this polymorphism may be restricted to the use of monoclonal antibody therapy.
The present study found that the majority of AIHA in WM are IgG-mediated AIHA and suggested that FcgRIIa-131R/H polymorphism may influence the onset of AIHA in WM. Although the frequency of AIHA found herein agreed with previous studies in WM, 1,2 the high incidence of IgG-positive DAT in WM patients has not been described previously. Consequently the IgG isotypes involved in these WM patients are not reported to our knowledge. However, several isotypes are found simultaneously in 59% of patients with IgG-positive DAT. 7 These IgG isotypes influence the pathogenicity and the efficiency of immune clearance through the binding of several Fcg receptors on effectors cells. 3, 4 Thus, the presence of the FcgRIIa131H as single allele which bind with more IgG isotypes may explain the association between FcgRIIa-131HH genotype and AIHA in WM patients by increasing the clearance of IgG opsonized red cells. Relationships between FcgRIIA-131HH genotype and immune thrombocytopenia 3 or a faster clearance rate of RhD-positive red blood cells 3 have also been reported. The sample size of this large series of rare patients with prolonged follow-up remains statistically limited. The present results require external confirmation, despite our internal validation with bootstrap resampling. The high frequencies, of cytopenias and cryoglobulinemia, which adverse prognostic value has also been reported, 2 agreed with the outcome of FcgRIIa-131HH patients. However, we cannot rule out a linkage disequilibrium between the FcgRIIa-131R/H polymorphism and other candidates genes on the long arm of chromosome 1. The survival of homozygous patients (FcgRIIa-131RR and FcgRIIa-131HH patients) was similar and shorter than the survival of heterozygous patients. As FcgRIIa is a single chain activating receptor, 3 the production of cytokines involved in the pathogenesis of B-cell malignancies 5 might be easier in FcgRIIa-131HH Number of treatment NS 0 7 (30%) 9 (28%) 6 (31%) 1 12 (53%) 13 (41) 6 (31%) 2 or more 4 (17%) 10 (31%) 7 (38%)
Abbreviations: FcgRIIa, immunoglobulin G fragment C receptor IIa; FcgRIIIa, immunoglobulin G fragment C receptor IIIa; IgG, immunoglobulin G; V: valine allele; F: phenylalanine allele; H histidine allele and R arginine allele; NS, not significant.
patients, through the binding of any IgG isotypes contained in immune complexes of autoimmune disorders associated with WM. This hypothesis may explain that FcgRIIa-131HH patients had a shorter survival than FcgRIIa-131RH patients. A similar effect might be observed in FcgRIIa-131RR patients, through the binding with CRP, because FcgRIIa-131R is a receptor for CRP, and CRP works similarly to IgG in causing events downstream to the binding of several FcgRIIa receptors. 5 The expression of the FcgRIIa on some B cells and mast cells 8 may contribute also to the effects of its ligands on WM cells.
In conclusion, the present study indicated that AIHA occurred more frequently in WM patients with the FcgRIIa-131HH genotype. In addition, FcgRIIa-131R/H polymorphism might influence the outcome of the patients.
Diagnosis of essential thrombocythemia (ET) relies on a set of criteria defined by the Polycythemia Vera Study Group and recently updated by WHO classification. Most of those criteria allow the exclusion of other myeloproliferative disorders (MPD) including polycythemia vera (PV), chronic myelogenous leukemia and myelofibrosis with myeloid metaplasia.
Differentiating primary from secondary causes of thrombocytosis has important therapeutic implications but can sometimes be difficult. A key evidence for MPD is the demonstration of clonal proliferation of hematopoietic stem cells. In the absence of a molecular marker and due to the rarity of chromosomal abnormalities in ET, assays based on X-linked polymorphic markers in female patients were developed to investigate clonality. [1] [2] [3] We have previously shown that the simultaneous study of several marker genes using methylation and expressionbased assays associated to the study of both granulocytes and platelets provides the finest evaluation of clonality status of hematopoiesis.
1,2 Using X-chromosome inactivation patterns (XCIPs) analysis, several groups reported that circulating granulocytes and platelets derived from ET patients displayed a monoclonal pattern. However, the persistence of polyclonal patterns in a subset of patients was also reported, possibly associated with a lower risk of thrombosis. 3 In the absence of specific molecular markers, demonstration of clonal myeloproliferation was impossible in those cases. The discovery of an activating V617F JAK2 mutation in most patients with PV 4 not only helps understand disease pathophysiology but represents also a clear molecular marker for this disease. In ET, the role of V617F JAK2 mutation is far less evident. Indeed, only half of ET patients harbor the mutation and its role in growth factor-independent in vitro proliferation of megakaryocytes has not yet been demonstrated. If diagnosis of PV will certainly rely on the presence of the mutation, in ET a positive marker is still necessary in almost half of patients, in whom V617F JAK2 is not present. It was recently reported that a similar proportion of ET patients with monoclonal XCIPs patterns could be found in JAK2 mutated and non-mutated patients. 5, 6 However, in those studies, only HUMARA assay was performed to assess clonality, a methylation-based test that is not completely reliable for patients' samples analysis because of possible abnormal DNA methylation in malignancies. 7 We studied a series of female ET patients in whom XCIPs had previously been analyzed by our group using both gene methylation and expression assays in all hematopoietic cell lineages 1,2 for the presence of mutant JAK2 and tested if the mutation correlated with monoclonal phenotype that would be expected if JAK2 mutation plays a role in disease development.
The studied population (n ¼ 44) and XCIPs analysis based on DNA and RNA assays were previously reported.
1,2 In summary,
